Merck Gains as Januvia Diabetes Drug Doesn’t Add to Heart Risk
This article is for subscribers only.
Merck & Co. shares rose in late trading after trial results showed diabetes drug Januvia didn’t increase patients’ heart risk compared with a placebo.
The stock rose as much as 4.4 percent to $59.60. Januvia is the company’s top-selling drug with $3.93 billion in sales last year, according to data compiled by Bloomberg.